Replimune Group (NASDAQ:REPL) Price Target Raised to $14.00

Replimune Group (NASDAQ:REPL) had its target price raised by research analysts at Piper Sandler from $13.00 to $14.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler’s price objective would indicate a potential upside of 98.02% from the company’s current price.

Several other analysts have also recently weighed in on REPL. Weiss Ratings reissued a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th. JPMorgan Chase & Co. upgraded shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price objective on the stock in a report on Monday, October 20th. Leerink Partners raised shares of Replimune Group from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $3.00 to $13.00 in a report on Monday, October 20th. HC Wainwright raised Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Monday, October 27th. Finally, Wedbush upped their price objective on Replimune Group from $18.00 to $19.00 and gave the company an “outperform” rating in a report on Wednesday. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Replimune Group currently has an average rating of “Hold” and a consensus target price of $10.00.

Replimune Group Price Performance

Shares of REPL stock traded up $0.07 during trading hours on Thursday, hitting $7.07. 484,718 shares of the company’s stock were exchanged, compared to its average volume of 1,348,453. Replimune Group has a 52 week low of $2.68 and a 52 week high of $14.80. The stock has a market cap of $554.57 million, a price-to-earnings ratio of -2.06 and a beta of 0.73. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.31 and a quick ratio of 6.31. The stock’s 50-day moving average is $8.88 and its 200-day moving average is $7.22.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.08. As a group, research analysts forecast that Replimune Group will post -2.97 EPS for the current year.

Insider Buying and Selling at Replimune Group

In related news, insider Konstantinos Xynos sold 7,248 shares of the stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $9.10, for a total transaction of $65,956.80. Following the completion of the transaction, the insider directly owned 139,685 shares of the company’s stock, valued at approximately $1,271,133.50. This represents a 4.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Sushil Patel sold 10,000 shares of the stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $11.13, for a total transaction of $111,300.00. Following the completion of the sale, the chief executive officer owned 333,576 shares of the company’s stock, valued at approximately $3,712,700.88. This represents a 2.91% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 25,625 shares of company stock worth $257,607. Company insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds have recently bought and sold shares of REPL. Saturn V Capital Management LP acquired a new position in Replimune Group in the 2nd quarter worth about $1,198,000. Squarepoint Ops LLC grew its holdings in shares of Replimune Group by 394.0% during the second quarter. Squarepoint Ops LLC now owns 67,929 shares of the company’s stock worth $631,000 after purchasing an additional 54,178 shares during the last quarter. Nan Fung Trinity HK Ltd. bought a new stake in shares of Replimune Group during the second quarter worth about $4,325,000. Los Angeles Capital Management LLC acquired a new position in shares of Replimune Group in the second quarter valued at approximately $403,000. Finally, TD Asset Management Inc raised its holdings in Replimune Group by 18.7% in the 2nd quarter. TD Asset Management Inc now owns 327,452 shares of the company’s stock valued at $3,042,000 after buying an additional 51,600 shares during the last quarter. 92.53% of the stock is owned by institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.